Portal de investigación
QUALIFICATION OF IMAGING METHODS TO ASSESS CANCER DRUG INDUCED INTERSTITIAL LUNG DISEASE (IMAGEILD).
Datos básicos
- Protocolo:
- EOR-CIS-2018-01
- EUDRACT:
- NCT:
- Centro:
- HOSPITAL UNIVERSITARI I POLITÈCNIC LA FE
- Año de incio:
- 2018
- Año de finalización:
Objetivos del proyecto
Observaciones: Estado Comité: ACTIVO
Documentos
- No hay documentos
Participantes
Financiadores - Promotores
Resultados del Ensayo Clínico
3D patient-specific spinal cord computational model for SCS management: potential clinical applications.
Solanes C; (...); Saiz J
Article. 10.1088/1741-2552/abe44f. 2021
A Confidence Habitats Methodology in MR Quantitative Diffusion for the Classification of Neuroblastic Tumors.
Cerda Alberich, Leonor; (...); Marti-Bonmati, Luis
Article. 10.3390/cancers12123858. 2020
A Gadolinium(III) Complex Based on Pyridoxine Molecule with Single-Ion Magnet and Magnetic Resonance Imaging Properties.
Orts-Arroyo, Marta; (...); Martinez-Lillo, Jose
Article. 10.3390/ijms25042112. 2024
A Gadolinium(III) Complex Based on the Thymine Nucleobase with Properties Suitable for Magnetic Resonance Imaging
Orts-Arroyo, M; (...); Martinez-Lillo, J
Article. 10.3390/ijms22094586. 2021
A method for liver segmentation in perfusion MR images using probabilistic atlases and viscous reconstruction
Dura, E; (...); Marti-Bonmati, L
Article. 10.1007/s10044-017-0666-z. 2018
A phase Ib study of CC-90011, a potent, reversible, oral LSD1 inhibitor, plus etoposide and cisplatin (EP) or carboplatin (EC) in patients (Pts) with first-line (1L) extensive-stage (ES) small cell lung cancer (SCLC): Updated results
Ponce Aix, S.; (...); Paz-Ares, L.
Meeting Abstract. 2021
A practical solution to estimate the sample size required for clinical prediction models generated from observational research on data
Baeza-Delgado, Carlos; (...); Marti-Bonmati, Luis
Article. 10.1186/s41747-022-00276-y. 2022
A Randomized, Open-Label Phase II Study Evaluating Emibetuzumab Plus Erlotinib and Emibetuzumab Monotherapy in MET Immunohistochemistry Positive NSCLC Patients with Acquired Resistance to Erlotinib.
Camidge DR; (...); Smit E
Article. 10.1016/j.cllc.2022.03.003. 2022
ABOUND.2L+: A randomized phase 2 study of nanoparticle albumin-bound paclitaxel with or without CC-486 as second-line treatment for advanced nonsquamous non-small cell lung cancer (NSCLC)
Morgensztern, D; (...); ABOUND 2L Investigators
Article. 10.1002/cncr.31779. 2018
Agreement Between Different Methodologies for Non-Invasive p.T790M and EGFR Sensitizing Mutation Testing
Romero, A; (...); Provencio, M
Meeting Abstract. 10.1016/j.jtho.2019.08.1463. 2019
Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study.
Passaro, A; (...); Cho, B C
Article. 10.1016/j.annonc.2023.10.117. 2024
Amyloid brain-dedicated PET images can diagnose Alzheimer's pathology with Centiloid Scale.
Gandia-Ferrero MT; (...); Martí-Bonmatí L
Article. 10.1016/j.ejmp.2024.103345. 2024
An open-label, multicenter, phase 2 study of the safety and efficacy of navtemadlin (KRT-232) in patients with TP53 wild-type relapsed/refractory small cell lung cancer.
Dowlati, Afshin; (...); Carpeno, Javier de Castro
Meeting Abstract. 2022
Are there differences by sex in lung cancer characteristics at diagnosis? -a nationwide study.
Ruano-Ravina A; (...); Oramas J
Article. 10.21037/tlcr-21-559. 2021
Artificial intelligence and machine learning in cancer imaging.
Koh DM; (...); Prior F
Article. 10.1038/s43856-022-00199-0. 2022
Artificial Intelligence on FDG PET Images Identifies Mild Cognitive Impairment Patients with Neurodegenerative Disease.
Prats-Climent, Joan; (...); Marti-Bonmati, Luis
Article. 10.1007/s10916-022-01836-w. 2022
Assessment of a New ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in Patients with Non-Small Cell Lung Carcinoma: the ROSING Study
Conde, E; (...); Lopez-Rios, F
Article. 10.1016/j.jtho.2019.07.005. 2019
Assessment of Gender Differences in the Psychosocial and Economic Impact on Patients with Stage IV Non-Small Cell Lung Cancer
Garrido, P; (...); Vinolas, N
Meeting Abstract. 10.1016/j.jtho.2019.08.685. 2019
Assessment of the dicentric chromosome assay as a biodosimetry tool for more personalized medicine in a case of a high risk neuroblastoma I-131-mIBG treatment
Chimeno, JM; (...); Montoro, A
Article. 10.1080/09553002.2019.1549755. 2018
Assessment of the Feasibility and Safety of Durvalumab for Treatment of Solid Tumors in Patients With HIV-1 Infection The Phase 2 DURVAST Study
Gonzalez-Cao, M; (...); Rosell, R
Article. 10.1001/jamaoncol.2020.0465. 2020
Association of Pelvic Organ Prolapse and Changes in Bone Imaging Biomarkers in Postmenopausal Women with Low Bone Mineral Density
Arguedas, Maria Perez; (...); Marti-Bonmati, Luis
Article. 10.31083/j.ceog5104092. 2024
ASTRIS, a large real-world study to evaluate the efficacy of osimertinib in epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer patients: Clinical characteristics and genotyping methods in a Spanish cohort.
Vicente-Baz D; (...); Provencio M
Article. 10.1016/j.patol.2019.11.002. 2020
ASTRIS, a real-world study with osimertinib in patients with non-small cell lung cancer (NSCLC) EGFR T790M mutated: Characteristics and diagnostic methods used for patients included in Spain
Baz, DV; (...); Pulla, MP
Meeting Abstract. 10.1016/S1556-0864(18)30430-1. 2018
ATEZO-BRAIN, A Single-Arm Phase II Study of Atezolizumab Combined with Chemotherapy in Stage IV NSCLC Patients with Untreated Brain Metastases
Nadal, E; (...); Bruna, J
Meeting Abstract. 10.1016/j.jtho.2019.08.826. 2019
Auditory hallucinations in first-episode psychosis: A voxel-based morphometry study
Escarti, MJ; (...); PEPs Grp
Article. 10.1016/j.schres.2019.05.001. 2019
Automated Cervical Spinal Cord Segmentation in Real-World MRI of Multiple Sclerosis Patients by Optimized Hybrid Residual Attention-Aware Convolutional Neural Networks
Bueno, America; (...); Alberich-Bayarri, Angel
Article. 10.1007/s10278-022-00637-4. 2022
Automated prostate multi-regional segmentation in magnetic resonance using fully convolutional neural networks
Jimenez-Pastor, Ana; (...); Alberich-Bayarri, Angel
Article. 10.1007/s00330-023-09410-9. 2023
Automated vertebrae localization and identification by decision forests and image-based refinement on real-world CT data.
Jimenez-Pastor A; (...); Marti-Bonmati L
Article. 10.1007/s11547-019-01079-9. 2020
Automated Whole-Liver MRI Segmentation to Assess Steatosis and Iron Quantification in Chronic Liver Disease.
Martí-Aguado D; (...); Martí-Bonmatí L
Article. 10.1148/radiol.2021211027. 2022
Automatic magnetic resonance imaging series labelling for large repositories
Gomis-Maya, Armando; (...); Marti-Bonmati, Luis
Article. 10.1186/s40537-025-01086-w. 2025
Avelumab in Combination With Cetuximab and Chemotherapy as First-Line Treatment for Patients With Advanced Squamous NSCLC.
Andric, Zoran; (...); Ciardiello, Fortunato
Article. 10.1016/j.jtocrr.2022.100461. 2023
Baseline circulating myeloid-derived suppressor cells correlate with neutrophil-to-lymphocyte ratio and overall survival in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors
Garcia-Sanchez, J.; (...); Lahoz, A.
Meeting Abstract. 2021
Baseline circulating myeloid-derived suppressor cells subpopulations, neutrophils/lymphocytes ratio, and response to PD-1/PD-L1 inhibitor in non-small cell lung cancer patients.
SAnchez, JosE GarcIa; (...); Lahoz, Agustin
Meeting Abstract. 2020
Brain network functional connectivity changes in patients with anterior knee pain: a resting-state fMRI exploratory study.
Sanchis-Alfonso, Vicente; (...); Marti-Bonmati, Luis
Article. 10.1186/s41747-023-00378-1. 2023
Bridging gaps between images and data: a systematic update on imaging biobanks.
Gabelloni, Michela; (...); Neri, Emanuele
Article. 10.1007/s00330-021-08431-6. 2022
Capmatinib vs docetaxel as second- or third-line (2/3L) therapy in patients (pts) with METex14-mutated advanced NSCLC (aNSCLC): The GeoMETry-III trial
Vidal, O. J. Juan; (...); Wolf, J.
Meeting Abstract. 10.1016/j.annonc.2023.09.2424. 2023
Cardiorespiratory coupling in cetaceans; a physiological strategy to improve gas exchange?
Fahlman A; (...); Blawas A
Article. 10.1242/jeb.226365. 2020
Clinical Activity of Afatinib in Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Spanish Retrospective Multicenter Study
Moran, T; (...); Torres, JMS
Article. 10.1016/j.cllc.2020.04.011. 2020
Clinical characteristics and survival in stage I-IIIA lung cancer resected patients in Spain, analyzed in the Thoracic Tumors Registry (TTR)
Franco, FF; (...); Provencio, M
Meeting Abstract. 10.1016/j.annonc.2021.08.1771. 2021
Clinical experience of whole body and tumour dosimetry of 131-I-mIBG treatment for pediatric patients
Espallardo, I. Torres; (...); Prado-Wohlwend, S.
Meeting Abstract. 2023
Clinical utility of plasma-based digital next-generation sequencing (NGS) in patients with advance-stage lung adenocarcinomas with insufficient tumor samples for tissue genotyping.
Zugazagoitia, Jon; (...); Paz-Ares, Luis G.
Meeting Abstract. 10.1200/JCO.2018.36.15_suppl.9101. 2018
Clinical utility of plasma-based digital next-generation sequencing in oncogene-driven non-small-cell lung cancer patients with tyrosine kinase inhibitor resistance
Zugazagoitia, J; (...); Garrido, P
Article. 10.1016/j.lungcan.2019.05.032. 2019
Clinical utility of plasma-based digital next-generation sequencing in patients with advance-stage lung adenocarcinomas with insufficient tumor samples for tissue genotyping
Zugazagoitia, J; (...); Paz-Ares, L
Article. 10.1093/annonc/mdy512. 2019
ComBat harmonization in different PET imaging scenarios
Gandia-Ferrero, M.; (...); Marti-Bonmati, L.
Meeting Abstract. 2023
Comparative Multicentric Evaluation of Inter-Observer Variability in Manual and Automatic Segmentation of Neuroblastic Tumors in Magnetic Resonance Images
Veiga-Canuto, Diana; (...); Marti-Bonmati, Luis
Article. 10.3390/cancers14153648. 2022
Comparison of protocols with respiratory-gated (4D) motion compensation in PET/CT: open-source package for quantification of phantom image quality.
Martinez-Movilla, Andrea; (...); Carles, Montserrat
Article. 10.1186/s40658-022-00509-4. 2022
Comprehensive cross-platform comparison of methodologies for noninvasive EGFR mutation testing: Results of the RING observational trial.
Romero, Atocha; (...); Provencio-Pulla, Mariano
Meeting Abstract. 2020
Comprehensive cross-platform comparison of methods for non-invasive EGFR mutation testing: Results of the RING observational trial.
Romero A; (...); Provencio M
Article. 10.1002/1878-0261.12832. 2020
Comprehensive genomic profile by Foundation Medicine test in guiding routine decisions for secondline treatment in advanced non-small cell breast cancer (NSCLC): Preliminary results of lung-ONE study.
Rojo, Federico; (...); De Castro, Javier
Meeting Abstract. 2020
Considerations for artificial intelligence clinical impact in oncologic imaging: an AI4HI position paper
Marti-Bonmati L; (...); Tsakou G
Article. 10.1186/s13244-022-01220-9. 2022
Correction to: SEOM-GECP Clinical guidelines for diagnosis, treatment and follow-up of small-cell lung cancer (SCLC) (2022).
García-Campelo R; (...); Dómine M
Correction. 10.1007/s12094-023-03290-7. 2023
Correction: Pardo-Sánchez et al. Increased Tumor Growth Rate and Mesenchymal Properties of NSCLC-Patient-Derived Xenograft Models during Serial Transplantation. Cancers 2021, 13 , 2980.
Pardo-Sanchez, Jose Miguel; (...); Farràs R
Article. 10.3390/cancers13194825. 2021
Corrigendum to 'First-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus chemotherapy alone (4 cycles) in advanced non-small cell lung cancer: CheckMate 9LA 2-year update': [ESMO Open Volume 6, Issue 5, October 2021, 100273].
Reck, M.; (...); John, T.
Correction. 10.1016/j.esmoop.2021.100345. 2021
Critical review of HCC imaging in the multidisciplinary setting: treatment allocation and evaluation of response
Amorim J; (...); Martí-Bonmatí L
Review. 10.1007/s00261-020-02470-1. 2020
Current treatment landscape for oligometastatic non-small cell lung cancer
Garde-Noguera, Javier; (...); Counago, Felipe
Article. 10.5306/wjco.v13.i6.485. 2022
CXCR4: From Signaling to Clinical Applications in Neuroendocrine Neoplasms.
Sanchis-Pascual, David; (...); Merino-Torres, Juan Francisco
Article. 10.3390/cancers16101799. 2024
CXCR7 reactivates ERK signaling to promote resistance to EGFR kinase inhibitors in NSCLC.
Becker JH; (...); Shimamura T
Article. 10.1158/0008-5472.CAN-19-0024. 2019
CHAIMELEON Project: Creation of a Pan-European Repository of Health Imaging Data for the Development of AI-Powered Cancer Management Tools.
Bonmati, Luis Marti; (...); Alberich-Bayarri, Angel
Article. 10.3389/fonc.2022.742701. 2022
Characterization of patients with advanced non-small-cell lung cancer (NSCLC) harboring KRASG12C mutation and their associated direct healthcare costs in Spanish routine clinical practice (SILK study)
Aransay, N. Reguart; (...); Vila, A. Lloansi
Meeting Abstract. 10.1016/j.annonc.2023.09.2442. 2023
Chemokine Receptor CXCR7 Reactivates ERK Signaling to Promote Resistance to EGFR Kinase Inhibitors in NSCLC
Becker, J; (...); Shimamura, T
Meeting Abstract. 10.1016/j.jtho.2019.08.1478. 2019
Chronological and Biological Age as a Response Factor to Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer
Suay, G.; (...); Juan-Vidal, O.
Meeting Abstract. 2024
Data harmonisation for information fusion in digital healthcare: A state-of-the-art systematic review, meta-analysis and future research directions
Nan, Yang; (...); Yang, Guang
Review. 10.1016/j.inffus.2022.01.001. 2022
Data infrastructures for AI in medical imaging: a report on the experiences of five EU projects
Kondylakis, Haridimos; (...); Lekadir, Karim
Article. 10.1186/s41747-023-00336-x. 2023
Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study.
Ahn, Myung-Ju; (...); Sands, Jacob
Article. 10.1200/JCO-24-01544. 2024
Datopotamab Deruxtecan Vs Docetaxel in Patients with Non-Small Cell Lung Cancer: Final Overall Survival from TROPION-Lung01
Sands, J.; (...); Ahn, M-J
Meeting Abstract. 2024
Deep learning automatic semantic segmentation of glioblastoma multiforme regions on multimodal magnetic resonance images.
Beser-Robles, Maria; (...); Marti-Bonmati, Luis
Article. 10.1007/s11548-024-03205-z. 2024
Description of the clinical characteristics and survival in patients with metastatic NSCLC in the Spanish population: An analysis of the thoracic tumours registry (RTT study)
Franco, F; (...); Pulla, MP
Meeting Abstract. 10.1016/j.annonc.2020.08.1694. 2020
Design and validation of a decision support checklist for efficient resource allocation in research projects during proposal preparation.
Penades-Blasco, Ana; (...); Marti-Bonmati, Luis
Article. 10.1016/j.ejrad.2024.111362. 2024
Determination of essential biomarkers in lung cancer: A real-world data study in Spain
Calvo de Juan, V.; (...); Provencio Pulla, M.
Meeting Abstract. 10.1016/j.annonc.2022.02.048. 2022
Determination of essential biomarkers in lung cancer: a real-world data study in Spain with demographic, clinical, epidemiological and pathological characteristics
Provencio, Mariano; (...); Torrente, Maria
Article. 10.1186/s12885-022-09830-8. 2022
Development and evaluation of two open-source nnU-Net models for automatic segmentation of lung tumors on PET and CT images with and without respiratory motion compensation.
Carles, Montserrat; (...); Gkika, Eleni
Article. 10.1007/s00330-024-10751-2. 2024
Development and validation of an image biomarker to identify metabolic dysfunction associated steatohepatitis: MR-MASH score
Marti-Aguado, David; (...); Marti-Bonmati, Luis
Article. 10.1111/liv.15766. 2024
Development of a predictive model for early detection of lung cancer: SREAL-eLUNG study
Vidal, O. J. Juan; (...); Martinez, B. Valdivieso
Meeting Abstract. 2023
Development of severity and mortality prediction models for covid-19 patients at emergency department including the chest x-ray
Calvillo-Batllés P; (...); Martí-Bonmatí L
Article. 10.1016/j.rx.2021.09.011. 2022
Development of severity and mortality prediction models for covid-19 patients at emergency department including the chest x-ray.
Calvillo-Batllés P; (...); Martí-Bonmatí L
Article. 10.1016/j.rxeng.2021.09.004. 2022
Development, Implementation and Assessment of Molecular Diagnostics by Next Generation Sequencing in Personalized Treatment of Cancer: Experience of a Public Reference Healthcare Hospital.
Simarro J; (...); Palanca S
Article. 10.3390/cancers11081196. 2019
DICOM-MIABIS integration model for biobanks: a use case of the EU PRIMAGE project
Scapicchio C; (...); Neri E
Article. 10.1186/s41747-021-00214-4. 2021
Differences in multi-echo chemical shift encoded MRI proton density fat fraction estimation based on multifrequency fat peaks selection in non-alcoholic fatty liver disease patients
Marti-Aguado, D; (...); Marti-Bonmati, L
Article. 10.1016/j.crad.2020.07.031. 2020
Differences in technical and clinical perspectives on AI validation in cancer imaging: mind the gap!
Chouvarda, Ioanna; (...); Papanikolaou, Nikolaos
Article. 10.1186/s41747-024-00543-0. 2025
Digital Pathology Enables Automated and Quantitative Assessment of Inflammatory Activity in Patients with Chronic Liver Disease.
Marti-Aguado, David; (...); Marti-Bonmati, Luis
Article. 10.3390/biom11121808. 2021
Digital pathology: accurate technique for quantitative assessment of histological features in metabolic-associated fatty liver disease
Marti-Aguado, David; (...); Marti-Bonmati, Luis
Article. 10.1111/apt.16100. 2021
Documenting the de-identification process of clinical and imaging data for AI for health imaging projects
Kondylakis, Haridimos; (...); Tsiknakis, Manolis
Article. 10.1186/s13244-024-01711-x. 2024
Durvalumab (D) plus tremelimumab (T) in platinum-refractory/resistant extensive-stage small cell lung cancer (ES-SCLC): Efficacy, safety and ctDNA dynamics from Arm A of the phase 2 BALTIC study
Reinmuth, Niels; (...); Bondarenko, Igor
Meeting Abstract. 2022
ECONOMIC BURDEN OF ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC) PATIENTS HARBORING KRASG12C MUTATION IN SPAIN
Fernandez-Barcelo, C.; (...); Sampietro-Colom, L.
Meeting Abstract. 2023
ECONOMIC IMPACT OF THE NSCLC MOLECULAR DIAGNOSIS IN SPAIN: A RETROSPECTIVE ANALYSIS OF HEALTHCARE RESOURCES USE AND ASSOCIATED COSTS FROM THE LUNG-ONE STUDY
de Castro, J; (...); Rojo, F
Meeting Abstract. 2020
Effect of central nervous system (CNS) metastases in a real-world multicenter cohort study of Spanish ALK-positive non-small cell lung cancer (NSCLC) patients (p)
Angelats, L; (...); Costa, EC
Meeting Abstract. 2019
Effects of 3 Tesla magnetic resonance imaging exposure on the behavior and orientation of homing pigeons Columba livia domestica.
Parraga, Daniel Garcia; (...); Marti-Bonmati, Luis
Article. 10.1371/journal.pone.0241280. 2020
Efficacy and clinical and neuroimaging biomarkers of response of two intensive and spaced treatment protocols of theta burst magnetic stimulation in treatment resistant depression
Canada, Y.; (...); Sierra, P.
Meeting Abstract. 10.1192/j.eurpsy.2023.1269. 2023
Efficacy and safety of MCLA-129, an anti-EGFR/c-MET bispecific antibody, in non-small-cell lung cancer (NSCLC) with c-METexon 14 skipping mutations (METex14).
Brandao, Mariana da Rocha Almeida; (...); Felip, Enriqueta
Meeting Abstract. 2024
Efficacy and safety of nivolumab (nivo) monotherapy versus chemotherapy (chemo) in recurrent small cell lung cancer (SCLC): Results from CheckMate 331
Reck, M; (...); Spigel, DR
Meeting Abstract. 2018
Efficacy and Safety of Second- or Third-Line Nab-Paclitaxel plus Durvalumab in Patients with Advanced NSCLC (ABOUND.2L+)
Morgensztern, D; (...); Ong, TJ
Meeting Abstract. 10.1016/j.jtho.2018.08.626. 2018
Embracing critical thinking to enhance our practice
Editorial Material. 10.1186/s13244-023-01435-4. 2023
Empowering cancer research in Europe: the EUCAIM cancer imaging infrastructure
Marti-Bonmati, Luis; (...); EUCAIM Consortium European Soc Radiology, Hanna
Article. 10.1186/s13244-025-01913-x. 2025
Endothelin-1-Mediated Drug Resistance in EGFR-Mutant Non-Small Cell Lung Carcinoma
Pulido, I; (...); Shimamura, T
Article. 10.1158/0008-5472.CAN-20-0141. 2020
Epidemiology, treatment, and survival in small cell lung cancer in Spain: Data from the Thoracic Tumor Registry
Franco, F; (...); Provencio, M
Article. 10.1371/journal.pone.0251761. 2021
European Society of Medical Oncology (ESMO) guidelines for oncogene-addicted metastatic non-small cell lung cancer (NSCLC): a personalized treatment for each patient.
Suay, Guillermo, Aparisi, Francisco, Juan-Vidal, Oscar
Article. 10.21037/cco-23-100. 2024
Evaluation of a Novel ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in NSCLC Patients
Conde, E; (...); Lopez-Rios, F
Meeting Abstract. 10.1016/j.jtho.2018.08.785. 2018
Evaluation of pneumatosis intestinalis as a complication of lung transplantation
Ripolles, V. Belloch; (...); Marti-Bonmati, Y. L.
Article. 10.1016/j.rx.2023.01.006. 2024
Evaluation of pneumatosis intestinalis as a complication of lung transplantation.
Belloch Ripollés V; (...); Martí-Bonmatí L
Article. 10.1016/j.rxeng.2023.01.013. 2024
Evidence levels in radiology: the insights into imaging approach.
Editorial Material. 10.1186/s13244-021-00995-7. 2021
Evolving Characteristics of Gadolinium-Based Contrast Agents for MR Imaging: A Systematic Review of the Importance of Relaxivity.
Kanal, Emanuel; (...); Marti-Bonmati, Luis
Article. 10.1002/jmri.29367. 2024
Executive dysfunction and cortical variations among intimate partner violence perpetrators and the association with sexism.
Romero-Martinez, Angel; (...); Moya-Albiol, Luis
Article. 10.1093/scan/nsae046. 2024
Experimental phantom evaluation to identify robust positron emission tomography (PET) radiomic features
Carles, Montserrat; (...); Mix, Michael
Article. 10.1186/s40658-021-00390-7. 2021
Expert Consensus on the Management of Adverse Events of Lorlatinib in the Treatment of ALK+ Advanced Non-small Cell Lung Cancer.
Arriola E; (...); Felip E
Article. 10.1007/s40261-024-01379-7. 2024
Extended follow-up of DURVAST trial: A phase II study evaluating durvalumab treatment in HIV-1-infected patients with solid tumours by the Spanish lung cancer group
Cao, MG; (...); Costa, RR
Meeting Abstract. 10.1016/j.annonc.2020.08.1589. 2020
Extensive stage (ES) small-cell lung cancer (SCLC) in Spain: A review of demographic, epidemiological and clinical data from the Thoracic Tumors Registry (TTR study)
Calvo, V; (...); Pulla, MP
Meeting Abstract. 10.1016/j.annonc.2020.08.1555. 2020
F-18-FMISO-PET Hypoxia Monitoring for Head-and-Neck Cancer Patients: Radiomics Analyses Predict the Outcome of Chemo-Radiotherapy
Carles, M; (...); Nicolay, NH
Article. 10.3390/cancers13143449. 2021
FAMetA: a mass isotopologue-based tool for the comprehensive analysis of fatty acid metabolism.
Alcoriza-Balaguer MI; (...); Lahoz A
Article. 10.1093/bib/bbad064. 2023
Family History of Cancer and Lung Cancer: Information from the Thoracic Tumors Registry (TTR Study)
Calvo, V.; (...); Provencio, M.
Meeting Abstract. 2021
FDG-PET Radiomics for Response Monitoring in Non-Small-Cell Lung Cancer Treated with Radiation Therapy.
Carles M; (...); Gkika E
Article. 10.3390/cancers13040814. 2021
Feasibility and outcomes of transjugular intrahepatic portosystemic shunts in infants.
Martinez-Rodrigo, Jose J.; (...); Marti-Bonmati, Luis
Article. 10.1007/s00247-022-05575-5. 2022
Feasibility of outpatient dinutuximab (D) and irinotecan (I) for second-line treatment of relapsed or refractory small cell lung cancer (RR SCLC): Part 1 of an open-label, randomized, phase 2/3 study
Edelman, MJ; (...); Saunders, A
Meeting Abstract. 10.1016/S1556-0864(18)30363-0. 2018
Femoral insertion site of the graft used to replace the medial patellofemoral ligament influences the ligament dynamic changes during knee flexion and the clinical outcome (vol 25, pg 2443, 2017)
Sanchis-Alfonso, V; (...); Marti-Bonmati, L
Correction. 10.1007/s00167-018-5271-1. 2019
First-line (1L) nivolumab (N) plus ipilimumab (I) plus chemotherapy (C) vs C alone in patients (pts) with metastatic NSCLC (mNSCLC) from CheckMate 9LA: 4-y clinical update and outcomes by tumor histologic subtype (THS)
Carbone, David Paul; (...); Reck, Martin
Meeting Abstract. 2023
First-line (1L) nivolumab (N) plus ipilimumab (I) plus chemotherapy (C) vs C alone in patients (pts) with metastatic NSCLC (mNSCLC) from CheckMate 9LA: 4-y clinical update and outcomes by tumor histologic subtype (THS).
Carbone, David Paul; (...); Reck, Martin
Meeting Abstract. 10.1200/JCO.2023.41.17_suppl.LBA9023. 2023
First-line avelumab in combination with cetuximab and chemotherapy in patients with advanced squamous non-small cell lung cancer (NSCLC)
Andric, Z. G.; (...); Ciardiello, F.
Meeting Abstract. 2021
First-line Nivolumab (N) plus Ipilimumab (I) plus Chemotherapy (C) in Metastatic NSCLC (mNSCLC): CheckMate 9LA 4-Year Clinical Update
Baclin, Firas; (...); Reck, Martin
Meeting Abstract. 2024
First-line nivolumab (NIVO) plus ipilimumab (IPI) plus two cycles of chemotherapy (chemo) versus chemo alone (4 cycles) in patients with advanced non-small cell lung cancer (NSCLC): Two-year update from CheckMate 9LA.
Reck, Martin; (...); John, Tom
Meeting Abstract. 10.1200/JCO.2021.39.15_suppl.9000. 2021
First-line nivolumab (NIVO) plus ipilimumab (IPI)+2 cycles chemotherapy (chemo) vs 4 cycles chemo in advanced non-small cell lung cancer (aNSCLC): Association of blood and tissue tumor mutational burden (TMB) with efficacy in CheckMate 9LA
Paz-Ares, L.; (...); Carbone, D. P.
Meeting Abstract. 2021
First-line nivolumab (NIVO) plus ipilimumab (IPI)+2 cycles of chemotherapy (chemo) versus chemo alone (4 cycles) in patients with advanced non-small cell lung cancer (NSCLC): 2-year update from CheckMate 9LA
Reinmuth, N.; (...); John, T.
Meeting Abstract. 2021
First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial.
Paz-Ares, Luis; (...); Reck, Martin
Article. 10.1016/S1470-2045(20)30641-0. 2021
First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: CheckMate 817.
Ready, Neal E.; (...); Paz-Ares, Luis
Article. 10.1136/jitc-2022-006127. 2023
First-line Nivolumab plus Ipilimumab plus Chemo in Patients With Advanced NSCLC and Brain Metastases: Results From CheckMate 9LA
Carbone, D.; (...); Lu, S.
Meeting Abstract. 2021
First-Line Nivolumab Plus Ipilimumab With Chemotherapy Versus Chemotherapy Alone for Metastatic NSCLC in CheckMate 9LA: 3-Year Clinical Update and Outcomes in Patients With Brain Metastases or Select Somatic Mutations
Paz-Ares, Luis G.; (...); Carbone, David P.
Article. 10.1016/j.jtho.2022.10.014. 2023
First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update.
Reck M; (...); John T
Article. 10.1016/j.esmoop.2021.100273. 2021
First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in metastatic non-small cell lung cancer: CheckMate 9LA 2-year patient-reported outcomes.
Reck, Martin; (...); Carbone, David P.
Article. 10.1016/j.ejca.2023.01.015. 2023
Five-year outcomes with first-line (1L) nivolumab plus ipilimumab plus chemotherapy (N plus I plus C) vs C in patients (pts) with metastatic NSCLC (mNSCLC) in CheckMate 9LA.
Reck, Martin; (...); Paz-Ares, Luis G.
Meeting Abstract. https://doi.org/10.1200/JCO.2024.42.16_suppl.8560. 2024
Five-year outcomes with first-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus 4 cycles of chemotherapy alone in patients with metastatic non-small cell lung cancer in the randomized CheckMate 9LA trial.
Reck M; (...); Paz-Ares LG
Article. 10.1016/j.ejca.2024.114296. 2024
Four-year clinical update and treatment switching-adjusted outcomes with first-line nivolumab plus ipilimumab with chemotherapy for metastatic non-small cell lung cancer in the CheckMate 9LA randomized trial.
Carbone DP; (...); Reck M
Article. 10.1136/jitc-2023-008189. 2024
Free automatic software for quality assurance of computed tomography calibration, edges and radiomics metrics reproducibility.
Saborido-Moral, Juan D.; (...); Carles, Montserrat
Article. 10.1016/j.ejmp.2023.103153. 2023
FURTHER: A global study to evaluate furmonertinib in patients with EGFR mutant NSCLC including uncommon EGFR mutations (FURMO-002)
Le, Xiuning; (...); Wang, Jie
Meeting Abstract. https://doi.org/10.1200/JCO.2024.42.16_suppl.TPS8666. 2024
FURTHER: A Global, Randomized Study of Firmonertinib at Two Dose Levels in TKI-Naive, Advanced NSCLC with EGFR PACC Mutations
Le, X.; (...); Wang, J.
Meeting Abstract. 2024
GALLANT-1: Galectin-3 (Gal-3) inhibitor GB1211 plus atezolizumab (atezo) in patients with non-small cell lung cancer (NSCLC)-A randomized, double-blind trial.
Ghiringhelli, Francois; (...); Basse, Linda
Meeting Abstract. 2022
Genetic and Molecular Profiling of Non-Smoking Related Lung Adenocarcinomas
Pros, E; (...); Sanchez-Cespedes, M
Meeting Abstract. 10.1016/j.jtho.2019.08.878. 2019
Genome-wide profiling of non-smoking-related lung cancer cells reveals common RB1 rearrangements associated with histopathologic transformation in EGFR-mutant tumors.
Pros E; (...); Sanchez-Cespedes M
Article. 10.1016/j.annonc.2019.09.001. 2020
Genotypic Characteristics and Resistance Mutations in Advanced ALK plus NSCLC: The ALK-PATHFINDER Study
Lopez Castro, R.; (...); Ponce Aix, S.
Meeting Abstract. 2023
Geriatric assessment in clinical practice for patients with stage IV non-small-cell lung cancer: The Grup de Investigació I Divulgació Oncològica experience.
Girones, R; (...); Juan-Vidal, O
Article. 10.1111/ecc.12950. 2018
Gray matter volume differences in intimate partner violence perpetrators and its role in explaining dropout and recidivism
Romero-Martinez, Angel; (...); Moya-Albiol, Luis
Article. 10.1016/j.jpsychires.2024.09.019. 2024
Health-Related Quality of Life (HRQoL) Outcomes with Adagrasib vs Docetaxel in KRASG12C-Mutated Advanced NSCLC in KRYSTAL-12
Felip, E.; (...); Duruisseaux, M.
Meeting Abstract. https://doi.org/10.1016/j.jtho.2024.09.056. 2024
Hepatic and pancreatic fat as imaging biomarkers of metabolic syndrome.
Ballester-Vallés C; (...); Martí-Bonmatí L
Article. 10.1016/j.rx.2019.05.010. 2020
Hepatobiliary contrast agents for Liver Magnetic Resonance Imaging
Perez-Girbes, A., Lee, J. M., Marti-Bonmati, L.
Article. 10.1016/j.rx.2024.05.004. 2024
High risk of thrombosis in patients with advanced lung cancer harboring rearrangements in ROS1.
Muñoz-Unceta N; (...); Grupo de trombosis y cáncer SEOM
Article. 10.1016/j.ejca.2020.10.002. 2020
How to integrate quantitative information into imaging reports for oncologic patients.
Marti-Bonmati, L; (...); Alberich-Bayarri, A
Article. 10.1016/j.rx.2018.02.005. 2018
Hysterosalpingography and fertility: a technical relationship
Editorial Material. 10.1016/j.fertnstert.2018.06.034. 2018
IDENTIFICATION OF CANDIDATES FOR MASLD TREATMENT WITH INDETERMINATE VIBRATION- CONTROLLED TRANSIENT ELASTOGRAPHY
Marti-Aguado, David; (...); Marti-Bonmati, Luis
Meeting Abstract. 2024
Identification of Candidates for MASLD Treatment With Indeterminate Vibration-Controlled Transient Elastography.
Marti-Aguado, David; (...); Marti-Bonmati, Luis
Article. 10.1016/j.cgh.2024.10.014. 2024
Imaging biomarkers and radiomics in pediatric oncology: a view from the PRIMAGE (PRedictive In silico Multiscale Analytics to support cancer personalized diaGnosis and prognosis, Empowered by imaging biomarkers) project.
Veiga-Canuto, Diana; (...); Marti-Bonmati, Luis
Article. 10.1007/s00247-023-05770-y. 2023
Imaging Biomarkers for the Diagnosis and Prognosis of Neurodegenerative Diseases. The Example of Amyotrophic Lateral Sclerosis
Mazon, M; (...); Marti-Bonmati, L
Review. 10.3389/fnins.2018.00784. 2018
Imaging Biomarkers in Amyotrophic Lateral Sclerosis
Cerda Alberich, Leonor; (...); Marti-Bonmati, Luis
Editorial Material. 10.1007/978-1-0716-1712-0_20. 2022
Imaging features and clinical data-based network analysis of CAR-T treated B- cell lymphoma patients in relation to their TP53 mutation status
Estepa-Fernandez, A.; (...); Alberich-Bayarri, A.
Meeting Abstract. 2024
Immune checkpoint inhibitors as first-line treatment for brain metastases in stage IV NSCLC patients without driver mutations
Suay, Guillermo; (...); Lahoz, Agustin
Review. 10.1016/j.canlet.2024.217317. 2024
Immune checkpoint inhibitors in special populations. A focus on advanced lung cancer patients
Escoin-Perez C, Blasco S, Juan-Vidal O
Review. 10.1016/j.lungcan.2020.03.026. 2020
Immune-related adverse events (irAEs) and survival (OS) in metastatic non-small cell lung cancer (mNSCLC) patients (pts) treated with immunotherapy
Melian Sosa, M.; (...); Lorente, D.
Meeting Abstract. 2018
Immunogenicity of COVID-19 vaccines in lung cancer patients.
Provencio M; (...); Calvo V
Article. 10.1016/j.lungcan.2023.107323. 2023
Immunotherapy, chemotherapy and stereotactic radiotherapy to metastases, followed by definitive surgery or radiotherapy to the primary tumour, in patients with synchronous oligo-metastatic NSCLC: The ETOP CHESS trial
Guckenberger, M; (...); Stahel, RA
Meeting Abstract. 10.1016/j.annonc.2020.08.1731. 2020
Impact of Molecular Testing Using Next-Generation Sequencing in the Clinical Management of Patients with Non-Small Cell Lung Cancer in a Public Healthcare Hospital.
Simarro, Javier; (...); Palanca, Sarai
Article. 10.3390/cancers15061705. 2023
Improving the estimation of prognosis for glioblastoma patients by MR based hemodynamic tissue signatures
Fuster-Garcia, E; (...); Garcia-Gomez, JM
Article. 10.1002/nbm.4006. 2018
IN MEMORIAM To Julio Ponce, has works published, Doctor
Garrigues, V, Perpina, M, Marti-Bonmati, L
Biographical-Item. 10.1016/j.gastrohep.2019.02.001. 2019
Incidence, predictors and prognostic significance of thromboembolic disease in patients with advanced ALK-rearranged non-small cell lung cancer
Zugazagoitia, J; (...); Manzano, A
Letter. 10.1183/13993003.02431-2017. 2018
Incidence, risk factors, and thrombotic load of pulmonary embolism in patients hospitalized for COVID-19 infection.
García-Ortega A; (...); Martínez-García MÁ
Article. 10.1016/j.jinf.2021.01.003. 2021
Increased femoral anteversion in females with anterior knee pain relates to both the neck and the shaft of the femur.
Sanchis-Alfonso V; (...); Doménech-Fernández J
Article. 10.1007/s00402-023-05036-0. 2023
Increased Tumor Growth Rate and Mesenchymal Properties of NSCLC-Patient-Derived Xenograft Models during Serial Transplantation
Pardo-Sanchez, JM; (...); Farras, R
Article. 10.3390/cancers13122980. 2021
Independent Validation of a Deep Learning nnU-Net Tool for Neuroblastoma Detection and Segmentation in MR Images
Veiga-Canuto, Diana; (...); Marti-Bonmati, Luis
Article. 10.3390/cancers15051622. 2023
INDIVIDUALIZED DIAGNOSIS OF PSYCHOSIS BASED ON MACHINE LEARNING FROM FUNCTIONAL MAGNETIC RESONANCE DATA USING AN EMOTIONAL AUDITORY PARADIGM
Sanjuan, J; (...); Crespo-Facorro, B
Meeting Abstract. 10.1093/schbul/sbz020.615. 2019
Initial Efficacy and Safety Results of Irinotecan Liposome Injection (nal-IRI) in Patients with Small Cell Lung Cancer
Rodriguez, LPA; (...); Bunn, P
Meeting Abstract. 2019
Insights into my experience as the Editor-in-Chief: a recap to close an unforgettable chapter.
Editorial Material. 10.1186/s13244-024-01878-3. 2024
Insulin resistance and NAFLD: Relationship with intrahepatic iron and serum TNF-alpha using 1H MR spectroscopy and MRI
Martin-Rodriguez, JL; (...); Gonzalez-Calvin, JL
Article. 10.1016/j.diabet.2019.01.005. 2019
Interventional solutions for post-surgical problems: a lymphatic leaks review
Gomez, Fernando M.; (...); Bonmati, Luis Marti
Review. 10.1186/s42155-024-00473-3. 2024
Interventional solutions for post-surgical problems: a lymphatic leaks review (vol 7, 61, 2024)
Gomez, Fernando M.; (...); Bonmati, Luis Marti
Correction. 10.1186/s42155-024-00483-1. 2024
Intravenous SPION-labeled adipocyte-derived stem cells targeted to the brain by magnetic attraction in a rat stroke model: An ultrastructural insight into cell fate within the brain.
García-Belda P; (...); Gil-Perotín S
Article. 10.1016/j.nano.2021.102464. 2021
Invasive scedosporiosis in lung transplant recipients: A nine-year retrospective study in a tertiary care hospital.
Ibáñez-Martínez E; (...); Pemán J
Case Reports. 10.1016/j.riam.2021.06.002. 2021
Knee Cartilage and Subchondral Bone Evaluations by Magnetic Resonance Imaging Correlate with Histological Biomarkers in an Osteoarthritis Rabbit Model
Sifre V; (...); Martí-Bonmatí L
Article. 10.1177/19476035221118166. 2022
KRYSTAL-12: Phase 3 study of adagrasib versus docetaxel in patients with previously treated advanced/metastatic non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation
Mok, Tony S. K.; (...); Barlesi, Fabrice
Meeting Abstract. 10.1200/JCO.2024.42.17_suppl.LBA8509. 2024
Late Breaking Abstract - Incidence, risk factors and thrombotic load of pulmonary embolism in patients hospitalized with COVID-19
Bekki, Amina; (...); Angel Martinez-Garcia, Miguel
Meeting Abstract. 10.1183/13993003.congress-2021.OA2597. 2021
Letter from the new Editor-in-Chief for Insights into Imaging.
Editorial Material. 10.1007/s13244-018-0617-2. 2018
LIPID DROPLET MORPHOLOGY JUSTIFIES DISCORDANCES BETWEEN HEPATIC STEATOSIS GRADES AND MRI PROTON DENSITY FAT FRACTION
Marti-Aguado, David; (...); Marti-Bonmati, Luis
Meeting Abstract. 2024
LipidMS: An R Package for Lipid Annotation in Untargeted Liquid Chromatography-Data Independent Acquisition-Mass Spectrometry Lipidomics
Alcoriza-Balaguer, MI; (...); Lahoz, A
Article. 10.1021/acs.analchem.8b03409. 2019
Liposomal Irinotecan in Adults with Small Cell Lung Cancer who Progressed on Platinum-Based Therapy: Subgroup Analyses by Platinum Sensitivity
Spigel, DR; (...); Bunn, P
Meeting Abstract. 2021
Longitudinal studies of functional magnetic resonance imaging in first-episode psychosis: A systematic review
Gonzalez-Vivas, C; (...); Sanjuan, J
Review. 10.1016/j.eurpsy.2019.04.009. 2019
Long-Term Survival for Brain-Only Oligometastatic NSCLC Patients Treated with Ablative Therapy (AT): Prognostic Factors
Salvador Coloma, C.; (...); Juan-Vidal, O.
Meeting Abstract. 2018
Lung brain metastasis pseudoprogression after nivolumab and ipilimumab combination treatment
Melian, M; (...); Juan, O
Article. 10.1111/1759-7714.12873. 2018
Lung Cancer Symptoms at Diagnosis: Data from the Thoracic Tumors Registry (TTR Study).
Calvo, V; (...); Provencio, M
Meeting Abstract. 2021
Lung cancer symptoms at diagnosis: results of a nationwide registry study.
Ruano-Raviña A; (...); Cerezo S
Article. 10.1136/esmoopen-2020-001021. 2020
LungBEAM: A prospective multicenter study to monitor stage IV NSCLC patients with EGFR mutations using BEAMing technology
Garrido, P; (...); Felip, E
Article. 10.1002/cam4.4135. 2021
LungBEAM: A prospective multicenter trial to monitor EGFR mutations using BEAMing technology in stage IV NSCLC patients
Lopez, PG; (...); Calvo, JP
Meeting Abstract. 2018
Machine Learning-Based Integration of Prognostic Magnetic Resonance Imaging Biomarkers for Myometrial Invasion Stratification in Endometrial Cancer
Rodriguez-Ortega, A; (...); Marti-Bonmati, L
Article. 10.1002/jmri.27625. 2021
Magnetic Resonance imaging analysis of liver fibrosis and inflammation: overwhelming gray zones restrict clinical use.
Marti-Aguado D; (...); Marti-Bonmati L
Article. 10.1007/s00261-020-02713-1. 2020
MAGNETIC RESONANCE IMAGING-BASED BIOMARKER ACCURATELY IDENTIFIES PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS AND CLINICALLY SIGNIFICANT LIVER FIBROSIS: A MULTICENTER, INTERNATIONAL, VALIDATION STUDY
Arnouk, Joud; (...); Marti-Bonmati, Luis
Meeting Abstract. 2021
Magnetic resonance imaging-based biomarker accurately identifies patients with nonalcoholic steatohepatitis and significant liver fibrosis: a multicentre, international, validation study
Marti-Aguado, David; (...); Marti-Bonmati, Luis
Meeting Abstract. 2022
MAIC-10 brief quality checklist for publications using artificial intelligence and medical images.
Cerda-Alberich, Leonor; (...); Marti-Bonmati, Luis
Article. 10.1186/s13244-022-01355-9. 2023
Malignant pleural mesothelioma: Treatment patterns and outcomes from the Spanish Lung Cancer Group
Remon, J; (...); Reguart, N
Article. 10.1016/j.lungcan.2020.06.034. 2020
Mapping the scientific research on radiology departments: Global trends in publication, collaboration and trending topics
Cogollos, Lourdes Castello; (...); Marti-Bonmati, Luis
Article. 10.1016/j.ejrad.2021.109841. 2021
Medical imaging clinical trials unit: A professional need.
Penades-Blasco, Ana; (...); Marti-Bonmati, Luis
Article. 10.1016/j.ejrad.2021.110099. 2022
Metabolic vulnerabilities of mesenchymal-like EGFR-mutant NSCLC cells with acquired resistance to tyrosine kinase inhibitors
Pulido, I; (...); Carretero, J
Meeting Abstract. 10.1158/1538-7445.AM2018-LB-099. 2018
Metastases Sites as a Prognostic Factor in a Real-World Multicenter Cohort Study of Spanish ALK-Positive NSCLC Patients (p)
Angelats, L; (...); Carcereny, E
Meeting Abstract. 10.1016/j.jtho.2019.08.808. 2019
METhodological RadiomICs Score (METRICS): a quality scoring tool for radiomics research endorsed by EuSoMII
Kocak, Burak; (...); Cuocolo, Renato
Article. 10.1186/s13244-023-01572-w. 2024
Molecular Markers and Image Biomarkers. Importance in the Therapeutic Advance of Intraaxial Brain Tumors
Guajardo-Hernandez, U; (...); Zalazar, DR
Article. 2021
Monitoring Bottlenose Dolphin ( Tursiops truncatus) Welfare During a Functional Neuroimaging Study
Ames, Audra E.; (...); Tyack, Peter L.
Article. 10.1578/AM.50.6.2024.495. 2024
MR Denoising Increases Radiomic Biomarker Precision and Reproducibility in Oncologic Imaging
Fernández Patón M; (...); Martí-Bonmatí L
Article. 10.1007/s10278-021-00512-8. 2021
MRI-PDFF captures the whole spectrum of lipid composition beyond traditional histological evaluation of macrosteatosis
Marti-Aguado, David; (...); Marti-Bonmati, Luis
Meeting Abstract. 2023
MS201944-0170: A phase Ila study to investigate the clinical activity and safety of avelumab in combination with cetuximab plus gemcitabine and cisplatin in patients with advanced squamous NSCLC.
Ciardiello, Fortunato; (...); Galffy, Gabriella
Meeting Abstract. 10.1200/JCO.2019.37.15_suppl.TPS9123. 2019
Multidisciplinary expert opinion on the treatment consensus for patients with EGFR mutated NSCLC with brain metastases
Ponce, S; (...); Nadal, E
Review. 10.1016/j.critrevonc.2019.03.017. 2019
Multi-parametric MR Imaging Biomarkers Associated to Clinical Outcomes in Gliomas: A Systematic Review.
Oltra-Sastre M; (...); Garcia-Gomez JM
Article. 10.2174/1573405615666190109100503. 2019
nab -Paclitaxel Plus Durvalumab in Patients With Previously Treated Advanced Stage Non-small Cell Lung Cancer (ABOUND.2L+).
Morgensztern D; (...); Ong TJ
Article. 10.3389/fonc.2020.569715. 2021
Nab-Paclitaxel Maintenance in Squamous Non-Small Cell Lung Cancer (NSCLC): Updated Results of the Phase III ABOUND.sqm Study
Spigel, D; (...); Thomas, M
Meeting Abstract. 10.1016/j.jtho.2019.08.604. 2019
nab-paclitaxel plus carboplatin induction followed by nab-paclitaxel maintenance in squamous non-small cell lung cancer (NSCLC): Results from the ABOUND. sqm study
Spigel, DR; (...); Thomas, M
Meeting Abstract. 2018
Nanoparticle Albumin-bound Paclitaxel Plus Carboplatin Induction Followed by Nanoparticle Albumin-bound Paclitaxel Maintenance in Squamous Non-Small-cell Lung Cancer (ABOUND.sqm): A Phase III Randomized Clinical Trial.
Spigel DR; (...); ABOUND.sqm Investigators
Article. 10.1016/j.cllc.2020.09.007. 2021
NIVEX TRIAL (GECP 1605): Nivolumab in the Real World: Spanish Expanded Access Program Experience in Pretreated Advanced NSCLC Patients
Rodriguez-Abreu, D; (...); Majem, M
Meeting Abstract. 10.1016/j.jtho.2018.08.1467. 2018
NIVIPI-BRAIN, A Phase II Study of Nivolumab plus Ipilimumab Combined with Chemotherapy for Patients with NSCLC and Synchronous Brain Metastases
Nadal, E.; (...); Bruna, J.
Meeting Abstract. 2022
Nivolumab (NIVO) plus ipilimumab (IPI)+2 cycles of platinum-doublet chemotherapy (chemo) vs 4 cycles chemo as first-line (1L) treatment (tx) for stage IV/recurrent non-small cell lung cancer (NSCLC): CheckMate 9LA
Reck, M; (...); Paz-Ares, LG
Meeting Abstract. 2020
Nivolumab (NIVO) plus ipilimumab (IPI)+2 cycles of platinum-doublet chemotherapy (chemo) vs 4 cycles chemo as first-line (1L) treatment (tx) for stage IV/recurrent non-small cell lung cancer (NSCLC): CheckMate 9LA.
Reck, M; (...); Paz-Ares, LG
Meeting Abstract. 2020
Nivolumab (NIVO) plus ipilimumab (IPI)+2 Cycles of Platinum-Doublet Chemotherapy (Chemo) vs. 4 Cycles Chemo as First-Line (1L) Treatment) for Stage IV/Recurrent Non-Small Cell Lung Cancer (NSCLC): CheckMate 9LA
Reck, M; (...); Paz-Ares, LG
Meeting Abstract. 2021
Novel Combinations of Immunotherapies or DNA Damage Repair Inhibitors in Platinum-Refractory Extensive-Stage Small-Cell Lung Cancer: The Phase II BALTIC Study.
Reinmuth, Niels; (...); Bondarenko, Igor
Article. 10.1158/1078-0432.CCR-24-0013. 2024
Objective Image Quality Comparison Between Brain-Dedicated PET and PET/CT Scanners.
Gandia-Ferrero MT; (...); Martí-Bonmatí L
Article. 10.1007/s10916-023-01984-7. 2023
Open-source AI-based networks for automatic segmentation of NSCLC on 3D and 4D PET/CT images
Radicioni, Gianluca; (...); Carles, Montserrat
Meeting Abstract. 2024
Optimisation of ultrasound liver perfusion through a digital reference object and analysis tool.
Alberich-Bayarri Á; (...); Martí-Bonmatí L
Article. 10.1186/s41747-019-0086-5. 2019
Optimizing the management of hereditary haemochromatosis: the value of MRI R2*quantification to predict and monitor body iron stores
Franca, M; (...); Porto, G
Letter. 10.1111/bjh.14982. 2018
Osimertinib in advanced EGFR-T790M mutation-positive non-small cell lung cancer patients treated within the Special Use Medication Program in Spain: OSIREX-Spanish Lung Cancer Group.
Provencio M; (...); Calvo V
Article. 10.1186/s12885-021-07922-5. 2021
OsimertinibTreatment in Non-Small Cell Lung Cancer (NSCLC) EGFR-T790M+. Activity in Patients with CNS Metastases. OSIREX
Terrasa, J; (...); Provencio, M
Meeting Abstract. 2021
Overall survival prediction and risk stratification in patients with neuroblastoma through machine learning in the large multi-institutional PRIMAGE cohort.
Lozano-Montoya, Jose; (...); Alberich-Bayarri, Angel
Meeting Abstract. https://doi.org/10.1200/JCO.2024.42.16_suppl.10054. 2024
Pancreatic cancer, Radiomics and Artificial Intelligence: A Review.
Marti-Bonmati L; (...); Alberich-Bayarri A
Article. 10.1259/bjr.20220072. 2022
Pancreatic steatosis and iron overload increases cardiovascular risk in non-alcoholic fatty liver disease.
Marti-Aguado D; (...); Marti-Bonmati L
Article. 10.3389/fendo.2023.1213441. 2023
PECATI: A Multicentric, Open-Label, Single-Arm Phase II Study to Evaluate the Efficacy and Safety of Pembrolizumab and Lenvatinib in Pretreated B3-Thymoma and Thymic Carcinoma Patients.
Remon J; (...); Besse B
Article. 10.1016/j.cllc.2021.07.008. 2021
Peer review and authorship disclosure.
Editorial Material. 10.1016/j.rxeng.2023.05.004. 2023
Pembrolizumab re-challenge in patients with relapsed non-small cell lung cancer (NSCLC): A preliminary report of the REPLAY phase II trial - cohort I
Ponce Aix, S.; (...); Paz-Ares, L.
Meeting Abstract. 10.1016/j.annonc.2021.10.179. 2021
Phase II study of durvalumab (MEDI4736) in cancer patients HIV-1-infected.
Gonzalez-Cao, M; (...); Rosell, R
Meeting Abstract. 10.1200/JCO.2019.37.15_suppl.2501. 2019
Phase II Trial of Atezolizumab Combined With Carboplatin and Pemetrexed for Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer With Untreated Brain Metastases (Atezo-Brain, GECP17/05).
Nadal E; (...); Bruna J
Article. 10.1200/JCO.22.02561. 2023
Plain language summary: tarlatamab for patients with previously treated small cell lung cancer.
Ahn, Myung-Ju; (...); Paz-Ares, Luis
Article. 10.1080/14796694.2024.2402152. 2024
Portable magnetic resonance imaging of patients indoors, outdoors and at home.
Guallart-Naval, Teresa; (...); Alonso, Joseba
Article. 10.1038/s41598-022-17472-w. 2022
Precise whole liver automatic segmentation and quantification of PDFF and R2*on MR images
Jimenez-Pastor A; (...); Marti-Bonmati L
Article. 10.1007/s00330-021-07838-5. 2021
Predicting survival, neurotoxicity and response in B-cell lymphoma patients treated with CAR-T therapy using an imaging features-based model
Ferrer-Lores, Blanca; (...); Alberich-Bayarri, Angel
Article. 10.1186/s13550-024-01172-9. 2024
Prediction of oncogene mutation status in non-small cell lung cancer leveraging radiomics from CT scans: A systematic review and meta-analysis with a special focus on artificial-intelligence-based methods
Fuster-Matanzo, Almudena; (...); Alberich-Bayarri, Angel
Meeting Abstract. 2024
Predictive and prognostic clinical and pathological factors of nivolumab efficacy in non-small-cell lung cancer patients
Garde-Noguera, J; (...); Juan-Vidal, O
Article. 10.1007/s12094-017-1829-5. 2018
Predictive and prognostic clinical and pathological factors of nivolumab efficacy in non-small-cell lung cancer patients (vol 20, pg 1072, 2018)
Garde-Noguera, J; (...); Juan-Vidal, O
Correction. 10.1007/s12094-018-1916-2. 2018
Predictive Clinical Decision Support System Using Machine Learning and Imaging Biomarkers in Patients With Neurostimulation Therapy: A Pilot Study
De Andres, Jose; (...); Marti-Bonmati, Luis
Article. 2021
Predictive Clinical Decision Support System Using Machine Learning and Imaging Biomarkers in Patients With Neurostimulation Therapy: A Pilot Study.
De Andres J; (...); Marti-Bonmati L
Article. 2021
Predictive value of texture analysis on lumbar MRI in patients with chronic low back pain.
Climent-Peris VJ; (...); Doménech-Fernández J
Article. 10.1007/s00586-023-07936-6. 2023
Preliminary efficacy of durvalumab plus tremelimumab in platinum-refractory/resistant ED-SCLC from arm A of the phase II BALTIC study
Bondarenko, I; (...); Reinmuth, N
Meeting Abstract. 2018
Preliminary results from PROPEL: A phase I/II study of bempegaldesleukin (BEMPEG: NKTR-214) plus pembrolizumab (PEMBRO) with or without chemotherapy in patients with metastatic NSCLC
Felip, E.; (...); Ganti, A.
Meeting Abstract. 10.1016/j.annonc.2021.10.159. 2021
Presence and evolution of multiple pulmonary nodules with halo sign detected by computerized tomography in advanced heart failure
Vilella, RRL; (...); Bonet, LA
Meeting Abstract. 2018
Pretreatment T790M mutation detection by ultrasensitive PCR assay as predictor of efficacy in non-small lung cancer (NSCLC) patients treated with 1st or 2nd generation EGFR tyrosine kinase inhibitors (TKIs)
Vidal, OJJ; (...); Palanca, S
Meeting Abstract. 2019
Prevalence of burnout syndrome during the COVID-19 pandemic and associated factors
Oprisan, A.; (...); Marti-Bonmati, L.
Article. 10.1016/j.rx.2021.09.003. 2022
Prevalence of burnout syndrome in Spanish radiologists
Oprisan, A.; (...); Marti-Bonmati, L.
Article. 10.1016/j.rx.2021.09.001. 2023
Prevalence of burnout syndrome in Spanish radiologists.
Oprisan, A; (...); Marti-Bonmati, L
Article. 10.1016/j.rxeng.2021.09.013. 2023
PRIMAGE project: predictive in silico multiscale analytics to support childhood cancer personalised evaluation empowered by imaging biomarkers.
Martí-Bonmatí L; (...); Neri E
Article. 10.1186/s41747-020-00150-9. 2020
Profile of Comorbidities and Cancer History in Patients with mNSCLC in the Spanish Population (Thoracic Tumors Registry).
Franco, F; (...); Provencio, M
Meeting Abstract. 2021
Prognostic factors in oligometastatic non-small-cell lung cancer (OM-NSCLC)
Juan, O; (...); Codina, JG
Meeting Abstract. 10.1016/S1556-0864(18)30411-8. 2018
Prognostic factors in oligometastatic non-small-cell lung cancer (OM-NSCLC) patients treated with ablative therapy.
Antonio Mendez, Juan; (...); Juan Vidal, Oscar
Meeting Abstract. 10.1200/JCO.2018.36.15_suppl.e21089. 2018
Prognostic model of long-term advanced stage (IIIB-IV) EGFR mutated non-small cell lung cancer (NSCLC) survivors using real-life data
Gutierrez, L; (...); Provencio, M
Article. 10.1186/s12885-021-08713-8. 2021
Prognostic Value of Radiomics Signature By Diagnostic 18F-FDG PET/CT Analysis in Aggressive Non-Hodgkin's Lymphoma
Lores, BF; (...); Terol, MJ
Meeting Abstract. 10.1182/blood-2018-99-119851. 2018
PROPEL: A Phase 1/2 Trial of Bempegaldesleukin (NKTR-214) Plus Pembrolizumab in Lung Cancer and other Advanced Solid Tumors
Spigel, DR; (...); Reck, M
Meeting Abstract. 2021
Prospective Exploratory Analysis of Angiogenic Biomarkers in Peripheral Blood in Advanced NSCLC Patients Treated With Bevacizumab Plus Chemotherapy: The ANGIOMET Study
Jantus-Lewintre, E; (...); Grp Espanol Canc Pulmon GECP
Article. 10.3389/fonc.2021.695038. 2021
Proteometabolomics of initial and recurrent glioblastoma highlights an increased immune cell signature with altered lipid metabolism.
Cosenza-Contreras, Miguel; (...); Schilling, Oliver
Article. 10.1093/neuonc/noad208. 2023
Publishing in open access journals.
Quaia, Emilio; (...); Marti-Bonmati, Luis
Editorial Material. 10.1186/s13244-024-01794-6. 2024
Quality of Life in Patients with Advanced NSCLC Treated in Second-or Third-Line with Nab-Paclitaxel plus Durvalumab: ABOUND. 2L+
Talbot, D; (...); Ong, TJ
Meeting Abstract. 10.1016/j.jtho.2018.08.649. 2018
Quality of life with second or third line nab-paclitaxel-based regimens in advanced non-small-cell lung cancer
Aix, SP; (...); Morgensztern, D
Article. 10.2217/fon-2019-0796. 2020
Quantification of H(2)(17)O by (1)H-MR imaging at 3 T: a feasibility study.
Martí-Bonmatí L; (...); Ferrer E
Article. 10.1186/s41747-021-00246-w. 2021
Quantification of Liver Iron Overload with MRI: Review and Guidelines from the ESGAR and SAR
Reeder, Scott B.; (...); Marti-Bonmati, Luis
Review. 10.1148/radiol.221856. 2023
Quantifying steatosis in the liver and pancreas with MRI in patients with chronic liver disease.
Vieira J; (...); França M
Article. 10.1016/j.rx.2019.11.007. 2020
Quantitative evaluation of a non-CT based attenuation correction method for a new dedicated brain PET
Gandia-Ferrero, M.; (...); Marti-Bonmati, L.
Meeting Abstract. 2022
Quantitative Evaluation of Neonatal Brain Elasticity Using Shear Wave Elastography.
Garcés Iñigo E; (...); Martí-Bonmatí L
Article. 10.1002/jum.15464. 2020
Quantitative magnetic resonance imaging assessment of muscle composition in myotonic dystrophy mice
Bargiela, Ariadna; (...); Artero, Ruben
Article. 10.1038/s41598-023-27661-w. 2023
Quantitative structural analysis of trabecular alveolar bone in the mandible by multidetector computed tomography: differences according to tooth presence and type
Sanz-Requena, R; (...); Marti-Bonmati, L
Article. 10.1016/j.rx.2019.01.003. 2019
Randomized phase 3 study of the anti-disialoganglioside antibody dinutuximab and irinotecan vs irinotecan or topotecan for second-line treatment of small cell lung cancer.
Edelman, Martin J.; (...); DISTINCT Study Investigators
Article. 10.1016/j.lungcan.2022.03.003. 2022
Randomized, Double-Blind Phase Ib/III Study of Erlotinib With Ramucirumab or Placebo in Previously Untreated EGFR-Mutant Metastatic Non-Small-Cell Lung Cancer (RELAY): Phase Ib Results
Reck, M; (...); Nakagawa, K
Article. 10.1016/j.cllc.2017.11.003. 2018
Real Clinical Practice Study to Evaluate 2 Line Treatment Based on Comprenhensive Genomic Profiling in NSCLC. LungONE Study
Carpeno, JD; (...); Rojo, F
Meeting Abstract. 2019
Real-world outcomes of first-line pembrolizumab (Pem) for metastatic non-small cell lung cancer (mNSCLC) with >= 50% expression of programmed cell death-ligand 1 (PD-L1): A multicentre retrospective study
Perea, J.; (...); Gaudens, P. Capdevila
Meeting Abstract. 2023
Redox Status, Dose and Antioxidant Intake in Healthcare Workers Occupationally Exposed to Ionizing Radiation
Sebastia, N; (...); Rodrigo, R
Article. 10.3390/antiox9090778. 2020
Re-evaluating the significance of the dive response during voluntary surface apneas in the bottlenose dolphin, Tursiops truncatus.
Fahlman, A; (...); Cauture, F
Article. 10.1038/s41598-019-45064-8. 2019
Relationship between neuroimaging and emotion recognition in Mild Cognitive Impairment patients.
Gandia-Ferrero, Maria Teresa; (...); Marti-Bonmati, Luis
Article. 10.1016/j.bbr.2023.114844. 2024
Reproducibility Analysis of Radiomic Features on T2-weighted MR Images after Processing and Segmentation Alterations in Neuroblastoma Tumors.
Veiga-Canuto, Diana; (...); Marti-Bonmati, Luis
Article. 10.1148/ryai.230208. 2024
RESILIENT part 1: A phase 2 dose-exploration and dose-expansion study of second-line liposomal irinotecan in adults with small cell lung cancer.
Paz-Ares, Luis; (...); Bunn, Paul A.
Article. 10.1002/cncr.34123. 2022
RESILIENT part 1: Pharmacokinetics of second-line (2L) liposomal irinotecan in patients with small cell lung cancer (SCLC)
Ponce, S; (...); Bunn, PA
Meeting Abstract. 10.1016/j.annonc.2020.08.1554. 2020
RESILIENT Part 1: Safety and Efficacy of Second-Line Liposomal Irinotecan in Patients with Small Cell Lung Cancer
Paz-Ares, L; (...); Bunn, P
Meeting Abstract. 2021
RESILIENT Part 2: A phase 3 Study of Liposomal Irinotecan in Patients with Small-Cell Lung Cancer in the Second-Line Setting
Paz-Ares, L; (...); Bunn, P
Meeting Abstract. 2021
RESILIENT part I, an open-label, safety run-in of liposomal irinotecan in adults with small cell lung cancer (SCLC) who have progressed with platinum-based first-line (1L) therapy: Subgroup analyses by platinum sensitivity.
Spigel, DR; (...); Bunn, P
Meeting Abstract. 2020
RESILIENT part II: an open-label, randomized, phase III study of liposomal irinotecan injection in patients with small-cell lung cancer who have progressed with platinum-based first-line therapy.
Paz-Ares, Luis G.; (...); Bunn, Paul
Meeting Abstract. 2020
RESILIENT: Study of irinotecan liposome injection (nal-IRI) in patients with small cell lung cancer-Preliminary findings from part 1 dose-defining phase.
Paz-Ares, Luis G.; (...); Bunn, Paul A.
Meeting Abstract. 2019
RET Fusion Testing in Advanced Non-Small Cell Lung Carcinoma Patients: the RETING Study
Conde, E.; (...); Lopez-Rios, F.
Meeting Abstract. 2021
RET Fusion Testing in Patients With NSCLC: The RETING Study.
Conde, Esther; (...); Lopez-Rios, Fernando
Article. 10.1016/j.jtocrr.2024.100653. 2024
RET Fusion Testing with FISH and Real-Time PCR: a Comparison with RNA-Based Next-Generation Sequencing in RET Positive NSCLC
Hernandez, S.; (...); Conde, E.
Meeting Abstract. 2022
Risk assessment in brain-only oligometastatic non-small cell lung cancer (BOO-NSCLC) patients (pts): Recursive partioning analysis (RPA) model modification
Salvador Coloma, C.; (...); Juan-Vidal, O.
Meeting Abstract. 2018
Risk stratification in neuroblastoma patients through machine learning in the multicenter PRIMAGE cohort.
Lozano-Montoya, Jose; (...); Alberich-Bayarri, Angel
Article. 10.3389/fonc.2025.1528836. 2025
Role of imaging in the evaluation of vascular complications after liver transplantation.
Delgado-Moraleda JJ, Ballester-Vallés C, Marti-Bonmati L
Article. 10.1186/s13244-019-0759-x. 2019
Role of the nigrosome 1 absence as a biomarker in amyotrophic lateral sclerosis
Isabel Moreno-Gambin, Maria; (...); Vázquez-Costa JF
Article. 10.1007/s00415-021-10729-w. 2021
Sacituzumab govitecan (SG) vs docetaxel (doc) in patients (pts) with metastatic non-small cell lung cancer (mNSCLC) previously treated with platinum (PT)-based chemotherapy (chemo) and PD(L)-1inhibitors (IO): Primary results from the phase 3 EVOKE-01 study.
Paz-Ares, Luis G.; (...); Garassino, Marina Chiara
Meeting Abstract. 10.1200/JCO.2024.42.17_suppl.LBA8500. 2024
Sacituzumab Govitecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III EVOKE-01 Study.
Paz-Ares, Luis G.; (...); Garassino, Marina Chiara
Article. 10.1200/JCO.24.00733. 2024
Sacituzumab Govitecan vs Docetaxel in Patients with mNSCLC Non-responsive to Last Anti-PD-(L)1containing Regimen: EVOKE-01
Garassino, M. C.; (...); Paz-Ares, L. G.
Meeting Abstract. 2024
Second-Line Nivolumab in Relapsed Small-Cell Lung Cancer: CheckMate 331.
Spigel DR; (...); Reck M
Article. 10.1016/j.annonc.2021.01.071. 2021
Second-line treatment in advanced non-squamous (NS) non-small cell lung cancer (NSCLC) patients in Spain, analyzed in the Thoracic Tumor Registry (RTT)
Carcereny Costa, E.; (...); Provencio Pulla, M.
Meeting Abstract. 10.1016/j.annonc.2022.02.062. 2022
SEOM clinical guidelines for the treatment of non-small cell lung cancer (2018).
Majem M; (...); Provencio M
Article. 10.1007/s12094-018-1978-1. 2019
SEOM-GECP Clinical guidelines for diagnosis, treatment and follow-up of small-cell lung cancer (SCLC) (2022).
Garcia-Campelo, Rosario; (...); Domine, Manuel
Article. 10.1007/s12094-023-03216-3. 2023
Seroprevalence and immunological memory against SARS-CoV-2 in lung cancer patients (p): SOLID study.
Provencio, Mariano; (...); Cobo, Manuel
Meeting Abstract. 10.1200/JCO.2021.39.15_suppl.8531. 2021
Seroprevalence and immunological memory against SARS-CoV-2 in lung cancer patients: the SOLID study.
Provencio, Mariano; (...); Cobo, Manuel
Article. 10.21037/tlcr-21-504. 2022
Sex differences in the diagnosis, treatment and prognosis of cancer: the rationale for an individualised approach.
Vera, Ruth; (...); del Alba, Aranzazu Gonzalez
Article. 10.1007/s12094-023-03112-w. 2023
Sex Differences in the Efficacy of Immune Checkpoint Inhibitors in Neoadjuvant Therapy of Non-Small Cell Lung Cancer: A Meta-Analysis
Suay, Guillermo; (...); Juan-Vidal, Oscar
Review. 10.3390/cancers15184433. 2023
Significance of the impact of motion compensation on the variability of PET image features
Carles, M; (...); Marti-Bonmati, L
Article. 10.1088/1361-6560/aab180. 2018
Small cell lung cancer (SCLC) extensive stage (ES) in Spain: Efficacy of treatments, data from the thoracic tumours registry (TTR study)
Carcereny Costa, E.; (...); Provencio Pulla, M.
Meeting Abstract. 10.1016/j.annonc.2020.08.1547. 2020
Spanish registry of thoracic tumors (TTR): Interim analyses of comorbidities, risk associations, personal and family history of cancer
Castro, RL; (...); Provencio, M
Meeting Abstract. 2019
Spatially Preserved Multi-Region Transcriptomic Subtyping and Biomarkers of Chemoimmunotherapy Outcome in Extensive-Stage Small Cell Lung Cancer.
Peressini M; (...); Zugazagoitia J
Article. 10.1158/1078-0432.CCR-24-0104. 2024
Stereotactic body radiation therapy: A good dance partner of oligometastatic non-small cell lung cancer to the sound of SINDAS study.
Mielgo-Rubio X; (...); Couñago F
Editorial Material. 10.5306/wjco.v11.i12.983. 2020
Supervised Domain Adaptation for Automated Semantic Segmentation of the Atrial Cavity
Saiz-Vivo, Marta; (...); Naranjo, Valery
Article. 10.3390/e23070898. 2021
Survival outcomes in ALK-positive NSCLC patients (p) treated 1st line brigatinib and impact of the ALK fusion variant
Provencio-Pulla, Mariano; (...); Romero, Atocha
Meeting Abstract. 2023
Survival, quality of life (QoL) and geriatric outcomes of elderly patients (pt) with advanced non-small cell lung cancer (NSCLC), treated with pembrolizumab (P) in the first-line setting
Blanco, R; (...); Vidal, OJJ
Meeting Abstract. 10.1016/j.annonc.2020.08.1631. 2020
Synergies Among Health Data Projects with Cancer Use Cases Based on Health Standards.
Gyrard, Amelie; (...); Alvarez, Eva Garcia
Article. 10.3233/SHTI240649. 2024
Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer.
Ahn MJ; (...); Paz-Ares L
Article. 10.1056/NEJMoa2307980. 2023
Technical Validation and Clinical Implications of Ultrasensitive PCR Approaches for EGFR-Thr790Met Mutation Detection in Pretreatment FFPE Samples and in Liquid Biopsies from Non-Small Cell Lung Cancer Patients
Simarro, Javier; (...); Palanca, Sarai
Article. 10.3390/ijms23158526. 2022
The anti-disialoganglioside (GD2) antibody dinutuximab (D) for second-line treatment (2LT) of patients (pts) with relapsed/refractory small cell lung cancer (RR SCLC): Results from part II of the open-label, randomized, phase II/III distinct study.
Edelman, M; (...); Deng, CQ
Meeting Abstract. 2020
The Brain Resting-State Functional Connectivity Underlying Violence Proneness: Is It a Reliable Marker for Neurocriminology? A Systematic Review
Romero-Martinez, A; (...); Moya-Albiol, L
Review. 10.3390/bs9010011. 2019
The contribution of brain volume to explain autonomous imbalance during recovery from acute stress in batterers.
Romero-Martinez, Angel; (...); Moya-Albiol, Luis
Letter. 10.1007/s00429-024-02772-w. 2024
The radiology report: structure, style, and contents
Marti-Bonmati, L., Alberich-Bayarri, A., Torregrosa, A.
Article. 10.1016/j.rx.2022.01.013. 2022
The role of intimate partner violence perpetrators' resting state functional connectivity in treatment compliance and recidivism.
Romero-Martinez, Angel; (...); Moya-Albiol, Luis
Article. 10.1038/s41598-024-52443-3. 2024
The S-REAL study: Spanish real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy.
Gomez Rueda, Ana; (...); Garrido, Pilar
Article. 10.1007/s12094-024-03404-9. 2024
The width of the third ventricle associates with cognition and behaviour in motor neuron disease
Vazquez-Costa, JF; (...); Sevilla, T
Article. 10.1111/ane.13022. 2019
Theranostic Contribution of Extracellular Matrix Metalloprotease Inducer-Paramagnetic Nanoparticles Against Acute Myocardial Infarction in a Pig Model of Coronary Ischemia-Reperfusion.
Ramirez-Carracedo, Rafael; (...); Zaragoza, Carlos
Article. 10.1161/CIRCIMAGING.121.013379. 2022
Thoracic Tumors Registry (RTT): Analysis of Clinical Features and Survival in Patients with mNSCLC in Spain.
Franco, F; (...); Provencio, M
Meeting Abstract. 2021
Transcriptomic analysis of pre-treatment tissue samples to predict clinical benefit to durvalumab in HIV-infected cancer patients
Wilhelmina Bracht, Jillian; (...); Rosell, Rafael
Meeting Abstract. 10.1158/1538-7445.AM2020-929. 2020
Transforming experimental radiology: Design and implementation of an innovative ePACS image storage system for AI imaging research environments.
Gomez-Rico Junquero, Ignacio; (...); Marti-Bonmati, Luis
Article. 10.1016/j.ijmedinf.2024.105549. 2024
Transient pulmonary nodules with halo sign in patients with advanced heart failure: a report of two cases.
López-Vilella R; (...); Bonet LA
Article. 10.1016/j.clinimag.2019.11.008. 2020
Translating radiological research into practice-from discovery to clinical impact
Smits, Marion; (...); Marti-Bonmati, Luis
Article. 10.1186/s13244-023-01596-2. 2024
Translation of a tissue epigenetic signature to circulating free DNA suggests BCAT1 as a potential noninvasive diagnostic biomarker for lung cancer
Palanca-Ballester, Cora; (...); Sandoval, Juan
Article. 10.1186/s13148-022-01334-3. 2022
Treatment strategy optimization for patients with non-small-cell lung cancer harboring EGFR mutation: a Delphi consensus.
Isla D; (...); Juan-Vidal O
Article. 10.1007/s12094-020-02518-0. 2021
Updated analysis from the ATEZO-BRAIN trial: Atezolizumab plus carboplatin and pemetrexed in patients with advanced nonsquamous non-small cell lung cancer with untreated brain metastases.
Nadal, Ernest; (...); Bruna, Jordi
Meeting Abstract. 2022
Utility of Next-Generation Sequencing in the Reconstruction of Clonal Architecture in a Patient with an EGFR Mutated Advanced Non-Small Cell Lung Cancer: A Case Report.
Simarro J; (...); Palanca S
Article. 10.3390/diagnostics12051266. 2022
Virtual conferences: results of an international survey on radiologist preferences and perspectives
D'Anna, Gennaro; (...); Ranschaert, Erik
Article. 10.1007/s00330-022-08903-3. 2022
WHAT ARE THE MAIN BRAIN CHANGES IN FMRI AFTER TREATMENT IN FIRST EPISODE PSYCHOSIS? A SYSTEMATIC REVIEW
Gonzalez, C; (...); Sanjuan, J
Meeting Abstract. 10.1093/schbul/sby017.676. 2018
What do biomarkers add: Mapping quantitative imaging biomarkers research.
Meseguer E; (...); Martí-Bonmatí L
Article. 10.1016/j.ejrad.2021.110052. 2022
Y-90 PET/MR imaging optimization with a Bayesian penalized likelihood reconstruction algorithm.
Calatayud-Jordan, Jose; (...); Torres-Espallardo, Irene
Article. 10.1007/s13246-024-01452-7. 2024